WO1998014170A1 - Vaccin idiotypique associe a un transporteur lipidique et destine aux troubles des cellules b - Google Patents

Vaccin idiotypique associe a un transporteur lipidique et destine aux troubles des cellules b Download PDF

Info

Publication number
WO1998014170A1
WO1998014170A1 PCT/US1997/017513 US9717513W WO9814170A1 WO 1998014170 A1 WO1998014170 A1 WO 1998014170A1 US 9717513 W US9717513 W US 9717513W WO 9814170 A1 WO9814170 A1 WO 9814170A1
Authority
WO
WIPO (PCT)
Prior art keywords
idiotype
lipid
based carrier
binding moiety
tumor
Prior art date
Application number
PCT/US1997/017513
Other languages
English (en)
Inventor
David B. Agus
Andrew S. Janoff
Andrew D. Zelenetz
Imran Ahmad
Eric Mayhew
Original Assignee
Sloan-Kettering Institute For Cancer Research
The Liposome Company, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan-Kettering Institute For Cancer Research, The Liposome Company, Inc. filed Critical Sloan-Kettering Institute For Cancer Research
Priority to AU45071/97A priority Critical patent/AU4507197A/en
Publication of WO1998014170A1 publication Critical patent/WO1998014170A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Conformément à la présente invention, on prépare un vaccin spécifique à un patient et destiné à traiter des lymphomes qui ne sont pas du type de Hodgkin et autres troubles des cellules B, à partir d'un transporteur lipidique à la surface duquel on lie un idiotype tumoral dérivé de cellules B prélevées chez ledit patient. L'iodiotype peut être absorbé directement à la surface du transporteur lipidique ou lié par l'intermédiaire d'une fraction de liaison à un idiotype qui est liée à la surface du transporteur lipidique. Lorsqu'on utilise une fraction de liaison à un idiotype, ladite fraction est de préférence une protéine G ou une protéine A ou une combinaison de ces protéines. Il n'est pas nécessaire de préparer l'idiotype à partir d'un hybridome et il n'est pas nécessaire d'utiliser des anticorps anti-idiotype dérivés de la souris. Au contraire, il est possible d'obtenir l'idiotype directement à partir d'un lysat de tumeur ou d'un autre échantillon prélevé sur le patient. Il est ainsi possible de préparer une composition conforme à l'invention et de l'utiliser pour faire naître une réaction immunitaire en quelques heures ou quelques jours, plutôt que sur une période de plusieurs mois. Le transporteur lipidique est de préférence un liposome et il peut être composé de lipides propres à en faire un adjuvant efficace du vaccin anti-tumeur. La composition immunothérapeutique de la présente invention peut également comporter des d'autres adjuvants ou des agents immunothérapeutiques incorporés au liposome. Le transporteur lipidique peut, par exemple, contenir un facteur stimulant les colonies de granulocytes-macrophages (gmCSF) ou des cytokines telles que l'interleukine-12 (IL-12) qui renforcent la réaction immunitaire induite par le vaccin.
PCT/US1997/017513 1996-09-30 1997-09-30 Vaccin idiotypique associe a un transporteur lipidique et destine aux troubles des cellules b WO1998014170A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU45071/97A AU4507197A (en) 1996-09-30 1997-09-30 Idiotypic vaccine in lipid based carrier for b cell disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2720196P 1996-09-30 1996-09-30
US60/027,201 1996-09-30

Publications (1)

Publication Number Publication Date
WO1998014170A1 true WO1998014170A1 (fr) 1998-04-09

Family

ID=21836306

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/017513 WO1998014170A1 (fr) 1996-09-30 1997-09-30 Vaccin idiotypique associe a un transporteur lipidique et destine aux troubles des cellules b

Country Status (2)

Country Link
AU (1) AU4507197A (fr)
WO (1) WO1998014170A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000076319A1 (fr) * 1999-06-16 2000-12-21 Biocrystal Ltd. Formulations de vaccins et procedes d'immunisation d'un sujet contre les lymphocytes b specifiques d'un antigene excrete
WO2010042644A3 (fr) * 2008-10-07 2010-07-15 Biovest International, Inc. Procédés d'induction d'une réponse immunitaire prolongée contre un idiotype de cellules b, au moyen de vaccins autologues anti-idiotypiques
WO2014036488A1 (fr) * 2012-08-31 2014-03-06 Biovest International, Inc. Procédés de production de vaccins idiotypiques autologues haute fidélité
US8722091B2 (en) 2001-09-26 2014-05-13 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion lyophilization

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
COLD SPRING HARBOR LABORATORY, 1988, HARLOW et al., "Antibodies, A Laboratory Manual", pages 613, 615-618 and 622-623. *
DATABASE EMBASE, Abstract No. 83201557, EPSTEIN et al., "Clinical Consequences of Epstein-Barr Virus Infection and Possible Control by an Anti-Viral Vaccine"; & CLIN. EXP. IMMUNOL., 1993, Vol. 53, No. 2, pages 257-271. *
DATABASE MEDLINE ON DIALOG, US NATIONAL LIBRARY OF MEDICINE, (Bethesda, MD, USA), Abstract No. 95219329, GREGORIADIS G., "The Immunological Adjuvant and Vaccine Carrier Properties of Liposomes"; & J. DRUG TARGETING, 1994, Vol. 2, No. 5, pages 351-356. *
DATABASE MEDLINE ON DIALOG, US NATIONAL LIBRARY OF MEDICINE, (Bethesda, MD, USA), Abstract No. 97008117, KWAK et al., "Vaccination of a Syngeneic, Lymphoma-Derived Immunoglobulin Idiotype Combined with Granulocyte/Macrophage Colony-Stimulating Factor Primes Mice for a Protective T-Cell Response"; & PROC. NATL. *
J. IMMUNOL., September 1988, Vol. 141, No. 6, GEORGE et al., "Idiotypic Vaccination as a Treatment for a B Cell Lymphoma", pages 2168-2174. *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000076319A1 (fr) * 1999-06-16 2000-12-21 Biocrystal Ltd. Formulations de vaccins et procedes d'immunisation d'un sujet contre les lymphocytes b specifiques d'un antigene excrete
US8722091B2 (en) 2001-09-26 2014-05-13 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion lyophilization
WO2010042644A3 (fr) * 2008-10-07 2010-07-15 Biovest International, Inc. Procédés d'induction d'une réponse immunitaire prolongée contre un idiotype de cellules b, au moyen de vaccins autologues anti-idiotypiques
WO2014036488A1 (fr) * 2012-08-31 2014-03-06 Biovest International, Inc. Procédés de production de vaccins idiotypiques autologues haute fidélité
US9725768B2 (en) 2012-08-31 2017-08-08 Biovest International, Inc. Methods for producing high-fidelity autologous idiotype vaccines

Also Published As

Publication number Publication date
AU4507197A (en) 1998-04-24

Similar Documents

Publication Publication Date Title
Davis et al. Liposomes as adjuvants with immunopurified tetanus toxoid: influence of liposomal characteristics.
AU631377B2 (en) Affinity associated vaccine
Machy et al. Small liposomes are better than large liposomes for specific drug delivery in vitro
US4565696A (en) Production of immunogens by antigen conjugation to liposomes
KR101854943B1 (ko) 소수성 부분을 통해 변형된 펩티드를 포함하는 리포솜 기반 구조체
US5049390A (en) Liposome containing immunotherapy agents for treating IgE mediated allergies
Shek et al. Immune response mediated by liposome-associated protein antigens. III. Immunogenicity of bovine serum albumin covalently coupled to vesicle surface.
van Rooijen et al. [6] Use of liposomes as biodegradable and harmless adjuvants
Shahum et al. Immunopotentiation of the humoral response by liposomes: encapsulation versus covalent linkage.
CA2088163C (fr) Liposomes qui fournissent un soutien thymodependant aux antigenes d'un vaccin faible
EP0356340B1 (fr) Vaccin à affinité associée
Sullivan et al. Preparation and characterization of heat-sensitive immunoliposomes
Harsch et al. Targeting of monoclonal antibody-coated liposomes to sheep red blood cells
US5897873A (en) Affinity associated vaccine
WO1998014170A1 (fr) Vaccin idiotypique associe a un transporteur lipidique et destine aux troubles des cellules b
US6312718B1 (en) Vaccine for B-cell malignancies
US20130330402A1 (en) Antinuclear antibody utilized as a targeting agent for pharmaceutical compounds used in the treatment of cancer and other diseases
NZ518669A (en) Therapeutic or prophylactic vaccination against cancer using antibodies recovered from serum by immunoaffinity purification
LeGrue Carrier and adjuvant properties of liposome-borne tumor-specific antigens
WO1997029769A9 (fr) Vaccin contre des malignites affectant les lymphocytes b
JP2760355B2 (ja) 不均整誘導リポソーム
Watarai et al. Application of liposomes to generation of monoclonal antibody to glycosphingolipid: production of monoclonal antibody to GgOse4Cer
Kim et al. Enhanced lymph node delivery and immunogenicity of hepatitis B surface antigen entrapped in galactosylated liposomes
Patel Influence of lipid composition on opsonophagocytosis of liposomes
JPH0355450B2 (fr)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998516756

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase